Novartis Faces Setback as Experimental Neuromuscular Therapy Misses Primary Endpoint

A late-stage trial of Novartis's investigational treatment for myotonic dystrophy did not meet its key efficacy goal. This marks the company's second major clinical failure within a short period, intensifying scrutiny on its pipeline. The drug, del-desiran, was being evaluated for a rare inherited muscle disorder.

The pharmaceutical company's late-stage investigation of del-desiran, aimed at treating myotonic dystrophy, failed to achieve its primary efficacy target. This outcome represents a significant setback for the candidate drug.

Notably, this failure follows another recent clinical disappointment for the firm, which raises questions about the robustness of its research portfolio. The therapy was specifically designed to address a rare, genetically inherited muscle condition.